Cue Biopharma Stock Alpha and Beta Analysis
| CUE Stock | USD 0.34 0.03 9.68% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Cue Biopharma. It also helps investors analyze the systematic and unsystematic risks associated with investing in Cue Biopharma over a specified time horizon. Remember, high Cue Biopharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Cue Biopharma's market risk premium analysis include:
Beta 2.81 | Alpha (1.04) | Risk 7.6 | Sharpe Ratio (0.12) | Expected Return (0.95) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Cue Biopharma Backtesting, Cue Biopharma Valuation, Cue Biopharma Correlation, Cue Biopharma Hype Analysis, Cue Biopharma Volatility, Cue Biopharma History and analyze Cue Biopharma Performance. Cue Biopharma Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Cue Biopharma market risk premium is the additional return an investor will receive from holding Cue Biopharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cue Biopharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Cue Biopharma's performance over market.| α | -1.04 | β | 2.81 |
Cue Biopharma expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Cue Biopharma's Buy-and-hold return. Our buy-and-hold chart shows how Cue Biopharma performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Cue Biopharma Market Price Analysis
Market price analysis indicators help investors to evaluate how Cue Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Cue Biopharma shares will generate the highest return on investment. By understating and applying Cue Biopharma stock market price indicators, traders can identify Cue Biopharma position entry and exit signals to maximize returns.
Cue Biopharma Return and Market Media
The median price of Cue Biopharma for the period between Sun, Oct 5, 2025 and Sat, Jan 3, 2026 is 0.63 with a coefficient of variation of 29.02. The daily time series for the period is distributed with a sample standard deviation of 0.18, arithmetic mean of 0.61, and mean deviation of 0.14. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 2828 shares by Millar Kerri-ann of Cue Biopharma at 3.05 subject to Rule 16b-3 | 10/20/2025 |
2 | Acquisition by Sandercock Colin of 100000 shares of Cue Biopharma at 3.21 subject to Rule 16b-3 | 10/29/2025 |
3 | What dividend safety score for Cue Biopharma Inc. stock - Market Growth Report Community Trade Idea Sharing - newser.com | 11/03/2025 |
4 | Cue Biopharmaand ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors | 11/06/2025 |
5 | Cue BiopharmaReports Third Quarter 2025 Financial Results and Recent Business Highlights | 11/12/2025 |
6 | Is Cue Biopharma Inc. stock dividend yield sustainable - July 2025 Analyst Calls Real-Time Market Sentiment Reports - newser.com | 11/19/2025 |
7 | Acquisition by Sandercock Colin of 70000 shares of Cue Biopharma at 0.7 subject to Rule 16b-3 | 12/03/2025 |
8 | Autoimmune drug developer Cue Biopharma plans new stock and warrant sale - Stock Titan | 12/18/2025 |
9 | Cue Biopharma Announces Pricing of 10 Million Public Offering | 12/19/2025 |
10 | Acquisition by Sarraf Pasha of 4229 shares of Cue Biopharma at 0.3094 subject to Rule 16b-3 | 12/30/2025 |
11 | Cue Biopharma stock niche immunotherapy bet caught in a bruising small-cap biotech storm - AD HOC NEWS | 12/31/2025 |
About Cue Biopharma Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Cue or other stocks. Alpha measures the amount that position in Cue Biopharma has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 | 2025 | 2026 (projected) | Days Sales Outstanding | 112.89 | 37.14 | 42.71 | 40.58 | PTB Ratio | 3.26 | 3.51 | 4.03 | 6.55 |
Cue Biopharma Upcoming Company Events
As portrayed in its financial statements, the presentation of Cue Biopharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cue Biopharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Cue Biopharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Cue Biopharma. Please utilize our Beneish M Score to check the likelihood of Cue Biopharma's management manipulating its earnings.
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 19th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Cue Biopharma
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Cue Biopharma Backtesting, Cue Biopharma Valuation, Cue Biopharma Correlation, Cue Biopharma Hype Analysis, Cue Biopharma Volatility, Cue Biopharma History and analyze Cue Biopharma Performance. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Cue Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.